Premium
Low expression of miR‐204 is associated with expression of CD34 and poor performance status in denovo AML
Author(s) -
Abdelhafiz Ahmed S.,
Elsayed Ghada M.,
Saber Magdy M.,
Gameel Abdallah,
Hamdy Nayera
Publication year - 2020
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/ijlh.13161
Subject(s) - myeloid leukemia , cd34 , medicine , oncology , microrna , leukemia , disease , correlation , overall survival , stem cell , cancer research , immunology , biology , gene , genetics , geometry , mathematics
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. There is growing evidence that microRNAs (miRNAs) provide prognostic information in AML. MiR‐204 has a tumor suppressor function, and several studies have proven its role in solid cancers. The aim of this work is to evaluate the level of expression of miR‐204 in adults newly diagnosed with AML with normal karyotype and to correlate its level of expression with disease outcome and different prognostic factors. Patients and methods The study included 87 adult patients newly diagnosed with AML. Detection of miR‐204 was done using RT‐PCR in patients and seven age‐matched controls. Results Acute myeloid leukemia patients showed significantly lower miR‐204 expression, compared to control group ( P = .029). Low miR‐204 expression was significantly associated with positive CD34 ( P = .017), with poor performance status (PS) ( P = .009), and with the presence of diabetes mellitus (DM) ( P = .014). Low expression of miR‐204 was also significantly associated with shorter overall survival (OS) ( P = .020) and disease‐free survival (DFS) ( P = .013). Low miR‐204 expression was identified as an independent prognostic factor for prediction of shorter OS ( P = .034) and DFS ( P = .027) in AML. Conclusion To the best of our knowledge; this is the first time to prove the correlation between miR‐204 expression and CD34 expression. Further study of this correlation is needed to confirm the role of miR‐204 in CD34‐positive cells, including leukemic stem cells. This correlation may have therapeutic implications. MiR‐204 can be used as a biomarker for PS in AML patients.